Early Access

10-KPeriod: FY2016

ALTRIA GROUP, INC. Annual Report, Year Ended Dec 31, 2016

Filed February 27, 2017For Securities:MO

Summary

Altria Group, Inc. (MO) reported strong financial performance for the fiscal year ended December 31, 2016, primarily driven by a significant one-time gain from the AB InBev/SABMiller business combination. This transaction resulted in a substantial increase in net earnings and diluted EPS for the year. The core tobacco businesses, smokeable and smokeless products, demonstrated resilience with positive operating income growth, supported by higher pricing and, in the case of smokeless products, increased shipment volumes. The company continued its commitment to shareholder returns through robust dividend payments and share repurchases, reflecting confidence in its ongoing operational performance and cash flow generation. Despite the positive overall results, Altria continues to navigate a complex operating environment characterized by ongoing litigation, regulatory scrutiny, and evolving consumer preferences in the tobacco industry. The company is actively managing these challenges through strategic pricing, cost efficiencies, and investments in innovative tobacco products. The significant gain from the AB InBev investment provided a substantial boost to earnings, but underlying operational performance in the tobacco segments remains critical for long-term value creation.

Financial Statements
Beta

Key Highlights

  • 1Significant gain of $13.9 billion (pre-tax) recognized from the AB InBev/SABMiller business combination, substantially boosting 2016 net earnings and EPS.
  • 2Smokeable products segment operating companies income increased due to higher pricing, partially offset by lower shipment volumes.
  • 3Smokeless products segment saw growth in net revenues and operating companies income, driven by higher shipment volume and pricing.
  • 4Altria continued its capital return program, increasing quarterly dividends and executing share repurchases under a $3.0 billion program.
  • 5The company is actively managing regulatory challenges, including FDA regulations and ongoing litigation, as described in the 'Risk Factors' and 'Legal Proceedings' sections.
  • 6Acquisition of Nat Sherman in January 2017 further strengthens the smokeable products segment with super-premium cigarettes and premium cigars.

Frequently Asked Questions